Amendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.
$ESLA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the ST
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The presentation will highlight clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Estrella's late-breakin
Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company's common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock. The combined offering price for each share of common stock and accompan
3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
EFFECT - Estrella Immunopharma, Inc. (0001844417) (Filer)
S-1/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
S-1/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire